Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 14/20 | 0.75 |
| ▸ | IKZF1 | Q13422 | 6/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765789 | 1.00 | IKZF2 (0.75) | IKZF2IKZF1 | |
| SCHEMBL20765247 | 0.95 | IKZF1 (0.78) | IKZF2IKZF1 | |
| SCHEMBL25617053 | 0.91 | IKZF1 (0.64) | IKZF2IKZF1 | |
| SCHEMBL20765811 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL20765392 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL23895451 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL20765691 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL20765806 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL20765608 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 | |
| SCHEMBL20936143 | 0.91 | IKZF1 (0.73) | IKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116096862-A | ZBTB32 inhibitors and uses thereof | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4165169-A1 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | IKZF2 336/4885IKZF1 781/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | IKZF2 336/4885IKZF1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.